DOA / Workplace

Point-of-care rapid testing for doa / workplace. OEM/ODM manufacturer.

Overview

Drug-of-abuse testing supports workplace screening, clinical toxicology and rehabilitation programs. Urine is the standard specimen.

Clinical Context

Drug-of-abuse testing supports workplace screening, clinical toxicology and rehabilitation. Urine is the standard specimen.

Diagnostic Markers & Methods

Single-analyte tests (THC, COC, AMP, MET, MOP/OPI, BZO, Fentanyl, etc.) · multi-panel cups (2–14 analytes) with adulteration checks.

Antigen vs Antibody

DOA tests are competitive immunoassays detecting drug/metabolite, not antibody-based.

Diagnostic Workflow

Screening (immunoassay) → any presumptive positive → confirmatory GC-MS/LC-MS → report per cut-offs.

Testing Window

Detection window varies by analyte (hours to days); urine is the standard specimen.

Interpretation

Screening results are presumptive; any positive analyte requires confirmatory testing (GC-MS/LC-MS). Cut-offs align with regulatory (SAMHSA-style) standards.

False Negative / Positive Considerations

False negative: diluted or adulterated urine. False positive: cross-reactivity with related compounds.

Confirmatory Testing

GC-MS / LC-MS for any presumptive positive.

Testing Settings

Workplace, occupational health and clinical toxicology; confirmation is laboratory-based.

Sources

SAMHSA guidelines; CLIA waived-testing standards.

Progene's Take

Position: Lead with the multi-panel cup with adulteration checks — it is the highest-value DOA SKU for workplace programs, not the single-analyte strip.

Panel cups with pH/specific-gravity/oxidant strips detect tampering at the point of collection.
SAMHSA-style cut-offs make your product defensible in regulated workplace programs.
Every positive is presumptive — sell the confirmatory workflow, not just the strip.

This is the buyer-advisor view of the technical team — editorial guidance, not a substitute for product IFU or local regulatory requirements.